WO2007002912A3 - Anti-proliferative compounds, compositions, and methods of use thereof - Google Patents
Anti-proliferative compounds, compositions, and methods of use thereof Download PDFInfo
- Publication number
- WO2007002912A3 WO2007002912A3 PCT/US2006/025726 US2006025726W WO2007002912A3 WO 2007002912 A3 WO2007002912 A3 WO 2007002912A3 US 2006025726 W US2006025726 W US 2006025726W WO 2007002912 A3 WO2007002912 A3 WO 2007002912A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- carbon atoms
- independently
- groups
- substituted
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Abstract
Compounds and compositions of Formula I are described, useful as anti-proliferative agents, and in particular anti-HPV, wherein: Y1A and Y1B are independently Y1; RX1 is RX; RX2 is alkenyl of 2 to 18 carbon atoms or alkynyl of 2 to 18 carbon atoms; Y1 is = O, -O(RX), =S, -N(RX), -N(O)(RX), -N(ORX), -N(O)(ORX), or -N(N(RX)(RX)); RX is independently R1, R2, R4, W3, or a protecting group; R1 is independently -H or alkyl of 1 to 18 carbon atoms; R2 is independently R3 or R4 wherein each R4 is independently substituted with 0 to 3 R3 groups or taken together at a carbon atom, two R2 groups form a ring of 3 to 8 carbons and the ring may be substituted with 0 to 3 R3 groups; R3 is R3a, R3b, R3c or R3d, provided that when R3 is bound to a heteroatom, then R3 is R3c or R3d; R3a is -H, -F, -Cl, -Br, -I, -CF3, -CN, N3, -NO2 or -OR4; R3b is = O, -O(R4), =S, -N(R4), -N(O)(R4), -N(OR4), -N(O)(OR4), or -N(N(R4)(R4)); 3c is -R4, -N(R4)(R4), -SR4, -S(O)R4, -S(O)2R4, -S(O)(OR4), -S(O)2(OR4), -OC(R3b)R4, -OC(R3b)OR4, -OC(R3b)(N(R4)(R4)), -SC(R3b)R4, -SC(R3b)OR4, -SC(R3b)(N(R4)(R4)), -N(R4)C(R3b)R4, -N(R4)C(R3b)OR4, -N(R4)C(R3b)(N(R4)(R4)), W3 or -R5W3 ; R3d is -C(R3b)R4, -C(R3b)OR4, -C(R3b)W3, -C(R3b)OW3 or -C(R3b)(N(R4)(R4)); R4 is -H, or an alkyl of 1 to 18 carbon atoms, alkenyl of 2 to 18 carbon atoms, or alkynyl of 2 to 18 carbon atoms; R5 is alkylene of 1 to 18 carbon atoms, alkenylene of 2 to 18 carbon atoms, or alkynylene of 2 to 18 carbon atoms; W3 is W4 or W5; W4 is R6, -C(R3b)R6, -C(R3b)W5, -SOM2R6, or -SOM2W5, wherein R6 is R4 wherein each R4 is substituted with O to 3 R3 groups; W5 is carbocycle or heterocycle wherein W5 is independently substituted with O to 3 R2 groups; and M2 is 0, 1 or 2; or pharmaceutically acceptable salts thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/170,247 | 2005-06-29 | ||
US11/170,247 US20060030545A1 (en) | 2003-12-30 | 2005-06-29 | Anti-proliferative compounds, compositions, and methods of use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007002912A2 WO2007002912A2 (en) | 2007-01-04 |
WO2007002912A3 true WO2007002912A3 (en) | 2007-06-28 |
Family
ID=37173806
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/025726 WO2007002912A2 (en) | 2005-06-29 | 2006-06-29 | Anti-proliferative compounds, compositions, and methods of use thereof |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2007002912A2 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI444384B (en) | 2008-02-20 | 2014-07-11 | Gilead Sciences Inc | Nucleotide analogues and their use in the treatment of malignancies |
ES2874774T3 (en) | 2011-12-22 | 2021-11-05 | Geron Corp | Guanine Analogs as Telomerase Substrates and Telomere Length Affects |
CN103665043B (en) | 2012-08-30 | 2017-11-10 | 江苏豪森药业集团有限公司 | A kind of tenofovir prodrug and its application in medicine |
HRP20220651T1 (en) | 2014-09-15 | 2022-08-19 | The Regents Of The University Of California | Nucleotide analogs |
EP3875462A1 (en) | 2015-09-15 | 2021-09-08 | The Regents of The University of California | Nucleotide analogs |
US10745428B2 (en) | 2015-12-10 | 2020-08-18 | Idenix Pharmaceuticals Llc | Antiviral phosphodiamide prodrugs of tenofovir |
WO2017106069A1 (en) | 2015-12-15 | 2017-06-22 | Merck Sharp & Dohme Corp. | Antiviral oxime phosphoramide compounds |
US10736908B2 (en) | 2016-10-26 | 2020-08-11 | Merck Sharp & Dohme Corp. | Antiviral aryl-amide phosphodiamide compounds |
JP2020504734A (en) | 2016-12-22 | 2020-02-13 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | Antiviral benzyl-amine phosphodiamide compounds |
AU2017379850B2 (en) | 2016-12-22 | 2022-03-24 | Msd International Gmbh | Antiviral aliphatic ester prodrugs of tenofovir |
EP3823629A4 (en) | 2018-07-19 | 2022-05-04 | Merck Sharp & Dohme Corp. | Phosphinic amide prodrugs of tenofovir |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005066189A1 (en) * | 2003-12-30 | 2005-07-21 | Gilead Sciences, Inc. | Phosphonates, monophosphonamidates, bisphosphonamidates for the treatment of viral diseases |
-
2006
- 2006-06-29 WO PCT/US2006/025726 patent/WO2007002912A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005066189A1 (en) * | 2003-12-30 | 2005-07-21 | Gilead Sciences, Inc. | Phosphonates, monophosphonamidates, bisphosphonamidates for the treatment of viral diseases |
US20050222090A1 (en) * | 2003-12-30 | 2005-10-06 | Gilead Sciences, Inc. | Anti-proliferative compounds, compositions, and methods of use thereof |
US20060046981A1 (en) * | 2003-12-30 | 2006-03-02 | Gilead Sciences, Inc. | Anti-nonmelanoma carcinoma compounds, compositions, and methods of use thereof |
Non-Patent Citations (6)
Title |
---|
HOLY, ANTONIN ET AL: "Synthesis and cytostatic activity of N-[2-(phosphonomethoxy)alkyl] derivatives of N6-substituted adenines, 2,6-diaminopurines and related compounds", COLLECTION OF CZECHOSLOVAK CHEMICAL COMMUNICATIONS , 66(10), 1545-1592 CODEN: CCCCAK; ISSN: 0010-0765, 2001, XP009054316 * |
KEITH, KATHY A. ET AL: "Evaluation of nucleoside phosphonates and their analogs and prodrugs for inhibition of orthopoxvirus replication", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY , 47(7), 2193-2198 CODEN: AMACCQ; ISSN: 0066-4804, 2003, XP002327373 * |
SNOECK, R. ET AL: "Antivaccinia activities of acyclic nucleoside phosphonate derivatives in epithelial cells and organotypic cultures", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY , 46(11), 3356-3361 CODEN: AMACCQ; ISSN: 0066-4804, 2002, XP002327372 * |
VALERIANOVA M ET AL: "ANTITUMOUR ACTIVITY OF N6-SUBSTITUTED PMEDAP DERIVATIVES AGAINST T-CELL LYMPHOMA", ANTICANCER RESEARCH, HELENIC ANTICANCER INSTITUTE, ATHENS,, GR, vol. 21, no. 3B, May 2001 (2001-05-01), pages 2057 - 2064, XP009071015, ISSN: 0250-7005 * |
VALERIANOVA M ET AL: "PMEDAP AND ITS N6-SUBSTITUTED DERIVATIVES: GENOTOXIC EFFECT AND APOPTOSIS IN IN VITRO CONDITIONS", ANTICANCER RESEARCH, HELENIC ANTICANCER INSTITUTE, ATHENS,, GR, vol. 23, no. 6C, November 2003 (2003-11-01), pages 4933 - 4940, XP009071017, ISSN: 0250-7005 * |
ZIDEK, ZDENEK ET AL: "Immunobiological activity of N-[2-(phosphonomethoxy)alkyl] derivatives of N6-substituted adenines, and 2,6-diaminopurines", EUROPEAN JOURNAL OF PHARMACOLOGY , 475(1-3), 149-159 CODEN: EJPHAZ; ISSN: 0014-2999, 2003, XP002405408 * |
Also Published As
Publication number | Publication date |
---|---|
WO2007002912A2 (en) | 2007-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007002912A3 (en) | Anti-proliferative compounds, compositions, and methods of use thereof | |
CA2550222A1 (en) | Phosphonates, monophosphonamidates, bisphosphonamidates for the treatment of viral diseases | |
NZ596615A (en) | Substituted isoquinoline derivative | |
WO2008111239A1 (en) | Antistatic agent and use thereof | |
AR062176A1 (en) | DERIVATIVES OF NICOTINAMIDE, A PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS AND ITS USE TO TREAT DISEASES ASSOCIATED WITH SMOOTH MUSCLE MISCLE OR NON MUSCULAR | |
TW200700069A (en) | Benzothiazole, thiazolopyridine, benzooxazole and oxazolopyridine derivatives | |
BRPI0608732A2 (en) | compound or a pharmaceutically acceptable salt, hydrate, solvate, complex or prodrug thereof, salt of a compound, process for preparing a compound, use of a compound, pharmaceutical composition, and | |
RS53627B1 (en) | N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors | |
WO2008083252A3 (en) | Methods of use for cyclopamine analogs | |
CO6321261A2 (en) | HETEROCICLIC OR SIPROBICICLIC BICYCLIC DERIVATIVES LINKED PIRAZOLO [1,5-A] PYRIMIDINES PROCEDURES FOR THEIR PREPARATION AND USES OF THE SAME | |
IL204621A (en) | Bicyclic - gamma - amino acid derivatives, compositions comprising the same and uses thereof | |
RS54718B1 (en) | 1,2,4-thiazolidin-3-one derivatives and their use in the treatment of cancer | |
AR063545A1 (en) | DERIVATIVES OF TIAZOLS -1,3 AMINOSUSTITUIDOS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USES AS ANTICANCER AGENTS | |
WO2008081096A3 (en) | Quinolinyl derivatives, method for preparing same, pharmaceutic compositions containing same, and use thereof as hypoglycemiant and hypolipemiant agents | |
BRPI0809981A2 (en) | COMPOUNDS, THE MANUFACTURING PROCESS OF THESE, PHARMACEUTICAL COMPOSITION CONTAINING THEM, METHOD OF TREATMENT AND / OR PREVENTION OF DISEASES WHICH ARE ASSOCIATED WITH MODULATION OF SUBSTITE 5 RECEIVERS AND USE OF COMPOUNDS. | |
WO2008044054A3 (en) | Hydroxy-substituted benzoic acid amide compounds for use in therapy | |
IN2014DN01993A (en) | ||
UA95972C2 (en) | Aminopyridine derivatives having aurora a selective inhibitory action | |
WO2012075242A3 (en) | Controlled chemical release of hydrogen sulfide | |
BRPI0817168A2 (en) | "method for the preparation of a compound" | |
HRP20130768T1 (en) | Use of cyclohexanehexol derivatives in the treatment of ocular diseases | |
MX2010006787A (en) | Halogenated analogues of anti-fibrotic agents. | |
BRPI1005979A8 (en) | RIFAMYCIN DERIVATIVES | |
TW200700917A (en) | Photosensitive composition | |
ZA200804625B (en) | Stabilized, non-aqueous cleaning compositions for microelectronics substrates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06786058 Country of ref document: EP Kind code of ref document: A2 |